Literature DB >> 35151643

Unravelling the molecular mechanisms underlying chronic respiratory diseases for the development of novel therapeutics via in vitro experimental models.

Ching Leng Tan1, Yinghan Chan2, Mayuren Candasamy2, Jestin Chellian2, Thiagarajan Madheswaran3, Lakshmana Prabu Sakthivel4, Vyoma K Patel5, Amlan Chakraborty6, Ronan MacLoughlin7, Deepak Kumar8, Nitin Verma9, Vamshikrishna Malyla10, Piyush Kumar Gupta11, Niraj Kumar Jha12, Lakshmi Thangavelu13, Hari Prasad Devkota14, Shvetank Bhatt15, Parteek Prasher16, Gaurav Gupta17, Monica Gulati18, Sachin Kumar Singh18, Keshav Raj Paudel19, Philip M Hansbro19, Brian G Oliver20, Kamal Dua21, Dinesh Kumar Chellappan22.   

Abstract

Chronic respiratory diseases have collectively become a major public health concern and have now taken form as one of the leading causes of mortality worldwide. Most chronic respiratory diseases primarily occur due to prolonged airway inflammation. In addition, critical environmental factors such as cigarette smoke, industrial pollutants, farm dust, and pollens may also exacerbate such diseases. Moreover, alterations in the genetic sequence of an individual, abnormalities in the chromosomes or immunosuppression resulting from bacterial, fungal, and viral infections may also play a key role in the pathogenesis of respiratory diseases. Over the years, multiple in vitro models have been employed as the basis of existing as well as emerging advancements in chronic respiratory disease research. These include cell lines, gene expression techniques, single cell RNA sequencing, cytometry, culture techniques, as well as serum/sputum biomarkers that can be used to elucidate the molecular mechanisms underlying these diseases, and to identify novel diagnostic and management options for these diseases. This review summarizes the current understanding of the pathogenesis of various chronic respiratory diseases derived through in vitro experimental models, where the knowledge obtained from these studies can greatly benefit researchers in the discovery and development of novel screening techniques and advanced therapeutic strategies that could be translated into clinical use in the future.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Asthma; COPD; Chronic respiratory diseases; Cystic fibrosis; In vitro models; Lung cancer

Mesh:

Substances:

Year:  2022        PMID: 35151643     DOI: 10.1016/j.ejphar.2022.174821

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Evaluation of the Cytotoxic Activity and Anti-Migratory Effect of Berberine-Phytantriol Liquid Crystalline Nanoparticle Formulation on Non-Small-Cell Lung Cancer In Vitro.

Authors:  Abdullah M Alnuqaydan; Abdulmajeed G Almutary; Mohd Azam; Bikash Manandhar; Geena Hew Suet Yin; Lee Li Yen; Thiagarajan Madheswaran; Keshav Raj Paudel; Philip M Hansbro; Dinesh Kumar Chellappan; Kamal Dua
Journal:  Pharmaceutics       Date:  2022-05-24       Impact factor: 6.525

2.  Prediction of Pulmonary Function Parameters Based on a Combination Algorithm.

Authors:  Ruishi Zhou; Peng Wang; Yueqi Li; Xiuying Mou; Zhan Zhao; Xianxiang Chen; Lidong Du; Ting Yang; Qingyuan Zhan; Zhen Fang
Journal:  Bioengineering (Basel)       Date:  2022-03-25

3.  Editorial: Advanced therapeutic delivery for the management of chronic respiratory diseases.

Authors:  Keshav Raj Paudel; Dinesh Kumar Chellappan; Ronan MacLoughlin; Terezinha de Jesus Andreoli Pinto; Kamal Dua; Philip M Hansbro
Journal:  Front Med (Lausanne)       Date:  2022-08-09

Review 4.  Nutraceuticals and mitochondrial oxidative stress: bridging the gap in the management of bronchial asthma.

Authors:  Venkata Sita Rama Raju Allam; Keshav Raj Paudel; Gaurav Gupta; Sachin Kumar Singh; Sukriti Vishwas; Monica Gulati; Saurabh Gupta; M V N L Chaitanya; Niraj Kumar Jha; Piyush Kumar Gupta; Vyoma K Patel; Gang Liu; Mohammad Amjad Kamal; Philip M Hansbro; Brian Gregory George Oliver; Dinesh Kumar Chellappan; Kamal Dua
Journal:  Environ Sci Pollut Res Int       Date:  2022-07-07       Impact factor: 5.190

Review 5.  Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis.

Authors:  Iris A L Silva; Onofrio Laselva; Miquéias Lopes-Pacheco
Journal:  J Pers Med       Date:  2022-08-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.